Skip to main content

Search

Reset all filters
771 Result(s)
Sort by

Cristian Torreblanca

Cristian Torreblanca

Cristian Torreblanca Estrada is a Corporate Global Facilities and Engineering Senior Manager Controller in Germany – with plans for growth across the global business.
More Green Overview

More Green Overview

Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
Innovating for our business

Innovating for our business

We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
FuturePack

FuturePack

Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
Employees empower small dairy producers

Employees empower small dairy producers

Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.
Saving Stroke Patients around the world

Saving Stroke Patients around the world

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Introducing CIAS

Introducing CIAS

Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
Boehringer Ingelheim Innovation Prize

Boehringer Ingelheim Innovation Prize

Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Making more health through animal health

Making more health through animal health

Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
History of the logo
Overview of the history of the corporate logo of Boehringer Ingelheim, from the founding years of the company until today
Lothar Halmer

Lothar Halmer

Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
New data for nintedanib in children with fibrosing ILD

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Galym Zhunisbekov

Galym Zhunisbekov

Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, reflects on our philosophy and our impact on millions of lives.